Exchange: NASDAQ·Updated 07:30 PM EST

ANTX News

News
all
press releases
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a...
Business Wire
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a...
Business Wire
More News
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent...
Business Wire
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the Jefferies Global Healthcare...
Business Wire
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate...
Business Wire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Companys...
Business Wire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.On October 19, 2026, the Compensation Committee...
Business Wire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2...
Business Wire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026...
PR Newswire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2...
Business Wire
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Companys newly-appointed Chief Medical...
Business Wire

Advertisement|Remove ads.